Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V3-X vaccine in cholangiocarcinoma
NCT03042182Phase 2Unknown
- Sponsor
- Immunitor Inc.
- Start
- Feb 2017
- Primary completion
- Feb 2020
- Modality
- Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of V3-X in cholangiocarcinoma (CCA), sponsored by Immunitor Inc.. Status: unknown.
02
Drugs
V3-X
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03042182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042182.